These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1321 related items for PubMed ID: 15955130

  • 21. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW, Liem AH, Dunselman PH, van der Sloot JA, Lok DJ, Zwinderman AH.
    Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
    [Abstract] [Full Text] [Related]

  • 22. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ, Aregawi D, Agloria M, Khalil Q, Winiarska M, Munjal J, Gogineni S, Wang P.
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [Abstract] [Full Text] [Related]

  • 23. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
    Lloret R, Ycas J, Stein M, Haffner S, STARSHIP Study Group.
    Am J Cardiol; 2006 Sep 15; 98(6):768-73. PubMed ID: 16950182
    [Abstract] [Full Text] [Related]

  • 24. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
    Fox KM, Gandhi SK, Ohsfeldt RL, Davidson MH.
    Am J Manag Care; 2007 Dec 15; 13 Suppl 10():S270-5. PubMed ID: 18095777
    [Abstract] [Full Text] [Related]

  • 25. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, Tershakovec AM.
    Curr Med Res Opin; 2006 Oct 15; 22(10):2041-53. PubMed ID: 17022864
    [Abstract] [Full Text] [Related]

  • 26. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
    Fox KM, Gandhi SK, Ohsfeldt RL, Blasetto JW, Bays HE.
    Curr Med Res Opin; 2007 Sep 15; 23(9):2125-33. PubMed ID: 17655813
    [Abstract] [Full Text] [Related]

  • 27. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
    Bullano MF, Wertz DA, Yang GW, Kamat S, Borok GM, Gandhi S, McDonough KL, Willey VJ.
    Pharmacotherapy; 2006 Apr 15; 26(4):469-78. PubMed ID: 16553504
    [Abstract] [Full Text] [Related]

  • 28. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
    Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG.
    Am J Cardiol; 2003 Mar 06; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
    [Abstract] [Full Text] [Related]

  • 29. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
    Miller PS, Smith DG, Jones P.
    Am J Cardiol; 2005 Jun 01; 95(11):1314-9. PubMed ID: 15904635
    [Abstract] [Full Text] [Related]

  • 30. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
    Betteridge DJ, Gibson JM.
    Diabet Med; 2007 May 01; 24(5):541-9. PubMed ID: 17367312
    [Abstract] [Full Text] [Related]

  • 31. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S, Scruel O, Deckelbaum RJ, Dupont IE, Ducobu J, Carpentier YA.
    Int J Cardiol; 2005 Oct 10; 104(3):338-45. PubMed ID: 16186066
    [Abstract] [Full Text] [Related]

  • 32. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
    Farnier M, Averna M, Missault L, Vaverkova H, Viigimaa M, Massaad R, Vandormael K, Johnson-Levonas AO, Brudi P.
    Int J Clin Pract; 2009 Apr 10; 63(4):547-59. PubMed ID: 19222610
    [Abstract] [Full Text] [Related]

  • 33. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
    Stalenhoef AF, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, Wilpshaar W.
    Eur Heart J; 2005 Dec 10; 26(24):2664-72. PubMed ID: 16143705
    [Abstract] [Full Text] [Related]

  • 34. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG, Ballantyne CM, Hsueh W, Rosen J, Lin J, Shah A, Lowe RS, Hanson ME, Tershakovec AM.
    J Clin Lipidol; 2011 Dec 10; 5(6):474-82. PubMed ID: 22108151
    [Abstract] [Full Text] [Related]

  • 35. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 10; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 36. Review of efficacy of rosuvastatin 5 mg.
    Teramoto T, Watkins C.
    Int J Clin Pract; 2005 Jan 10; 59(1):92-101. PubMed ID: 15707472
    [Abstract] [Full Text] [Related]

  • 37. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E, Ezetimibe Study Group.
    Am Heart J; 2004 Sep 10; 148(3):447-55. PubMed ID: 15389231
    [Abstract] [Full Text] [Related]

  • 38. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
    Rader DJ, Davidson MH, Caplan RJ, Pears JS.
    Am J Cardiol; 2003 Mar 06; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
    Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, Jones PH.
    Am J Cardiovasc Drugs; 2010 Mar 06; 10(3):175-86. PubMed ID: 20524719
    [Abstract] [Full Text] [Related]

  • 40. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P, IN-PRACTICE study.
    Int J Clin Pract; 2010 Jul 06; 64(8):1052-61. PubMed ID: 20487050
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 67.